Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study

Xue Bai, Keith T. Flaherty, Yoshiyasu Umeda et al.|EClinicalMedicine|2023

Cited by 26